Stocks · News reference
UroGen Pharma Submits NDA To FDA For Its Investigational Drug UGN-103 For Intravesical Solution
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 12:05 PM
- Checked
- Aug 17, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
UroGen Pharma Announces Strategic Option And Research License Agreement And Related Equity Investment Agreement With IntraGel Therapeutics
Read original at benzinga8-K filing — UroGen Pharma Ltd. (URGN)
Filed: 2026-08-20 AccNo: 0001437749-26-028590 Size: 151 KB Item 8.01: Other Events
Read original at edgar